[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342212-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-342212-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","characterization-of-cancer-driving-nucleotides-cdns-across-genes-cancer-types-and-patients","Characterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patients","","Cancer genomics aims to identify all cancer-driving mutations in each patient; among them, point mutations are termed cancer-driving nucleotides (CDNs) and recur across tumors. Using a probability framework, the study defines any point mutation with ≥3 hits in the TCGA cohort as a high-probability CDN. Results characterize the 50–150 TCGA CDNs per cancer type, contrasting recurrent CDNs with canonical cancer driver genes and highlighting low current discovery that limits functional testing and targeted therapy.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/characterization-of-cancer-driving-nucleotides-cdns-across-genes-cancer-types-and-patients/342212/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/characterization-of-cancer-driving-nucleotides-cdns-across-genes-cancer-types-and-patients/342212.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What are cancer-driving nucleotides (CDNs) in this study?","Question",{"text":62,"@type":63},"CDNs are point mutations that recur in cancers and are used to represent cancer-driving nucleotide changes across patients.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How does the study decide whether a mutation is a high-probability CDN?",{"text":67,"@type":63},"Mutations with i ≥ 3 recurrent hits in The Cancer Genome Atlas (TCGA) database are treated as high-probability CDNs under the study’s recurrence-based framework.",{"name":69,"@type":60,"acceptedAnswer":70},"Why does the study emphasize increasing sample size?",{"text":71,"@type":63},"Expanding the sample size to about 10^5 enables identification of most CDNs, supporting patient-specific targeting across multiple CDN-harboring genes.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},342212,1792173242,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  \nCharacterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patients  \nLingjie Zhang1, Tong Deng1, Zhongqi Liufu1,2, Xiangnyu Chen1, Shijie Wu1, Xueyu Liu1, Changhao Shi1, Bingjie Chen1,3, Zheng Hu4, Qichun Cai5, Chenli Liu4, Mengfeng Li6, Miles E Tracy1, Xuemei Lu2, Chung-I Wu1,7*, Hai-Jun Wen1*  \n1State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China; 2Center for Excellence in Animal Evolution and Genetics, The Chinese Academy of Sciences, Kunming, China; 3GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China; 4CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China; 5Cancer Center, Clifford Hospital, Jinan University, Guangzhou, China; 6Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; 7 Department of Ecology and Evolution, University of Chicago, Chicago, United States  \n*For correspondence:  \n[ciwu@uchicago.edu](ciwu@uchicago.edu) (C-IW);  \n[wenhj5@mail.sysu.edu.cn](wenhj5@mail.sysu.edu.cn) (H-JW)  \nCompeting interest: The authors declare that no competing interests exist.  \nFunding: See page 17  \nSent for Review  \n29 May 2024  \nPreprint posted  \n02 June 2024  \nReviewed preprint posted  \n04 September 2024  \nReviewed preprint revised  \n25 October 2024  \nVersion of Record published  \n17 December 2024  \nReviewing Editor: Detlef Weigel, Max Planck Institute for Biology Tübingen, Germany  \n Copyright Zhang et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use andredistribution provided that the original author and source are credited.  \n\n| eLife Assessment\u003Cbr>This valuable study is a companion to a paper introducing a theoretical framework and methodology for identifying cancer-driving nucleotides (CDNs) . The evidence that recurrent SNVs or CDNs are common in true cancer driver genes is convincing, with more limited evidence that many more undiscovered cancer driver mutations will have CDNs, and that this approach could identify these undiscovered driver genes with about 100,000 samples. |\n| --- |\n| Abstract A central goal of cancer genomics is to identify, in each patient, all the cancer-driving mutations. Among them, point mutations are referred to as cancer-driving nucleotides (CDNs), which recur in cancers. The companion study shows that the probability of i recurrent hits in n patients would decrease exponentially with i; hence, any mutation with i ≥ 3 hits in The Cancer Genome Atlas (TCGA) database is a high-probability CDN. This study characterizes the 50–150 CDNs identifiable for each cancer type of TCGA (while anticipating 10 times more undiscovered ones) as follows:(i) CDNs tend to code for amino acids of divergent chemical properties. (ii) At the genic level, far more CDNs (more than fivefold) fall on noncanonical than canonical cancer-driving genes (CDGs) . Most undiscovered CDNs are expected to be on unknown CDGs. (iii) CDNs tend to be more widely shared among cancer types than canonical CDGs, mainly because of the higher resolution at the nucleotide than the whole-gene level. (iv) Most important, among the 50–100 coding region mutations carried by a cancer patient, 5–8 CDNs are expected but only 0–2 CDNs have been identified at present. This low level of identification has hampered functional test and gene-targeted therapy.\u003Cbr>We show that, by expanding the sample size to 105, most CDNs can be identified. Full CDN identification will then facilitate the design of patient-specific targeting against multiple CDN-harboring genes. |\n\nZhang et al. eLife 2024;13:RP99341. DOI: [https://doi.org/10.7554/eLife.99341](https://doi.org/10.7554/eLife.99341) 1 of 26  \n Research article Cancer Biology | Evolutionary Biology  \nIntroduction  \nTumorigen","cbCaipKJTFwiAFpp","https://ap.wps.com/l/cbCaipKJTFwiAFpp","pdf",1844921,26,"English","# Introduction\n## Methods and theoretical premise\n## CDN identification rule\n# Abstract key findings\n## CDN characterization across cancer types and genes\n## Impact on functional testing and targeted therapy","[{\"question\":\"What are cancer-driving nucleotides (CDNs) in this study?\",\"answer\":\"CDNs are point mutations that recur in cancers and are used to represent cancer-driving nucleotide changes across patients.\"},{\"question\":\"How does the study decide whether a mutation is a high-probability CDN?\",\"answer\":\"Mutations with i ≥ 3 recurrent hits in The Cancer Genome Atlas (TCGA) database are treated as high-probability CDNs under the study’s recurrence-based framework.\"},{\"question\":\"Why does the study emphasize increasing sample size?\",\"answer\":\"Expanding the sample size to about 10^5 enables identification of most CDNs, supporting patient-specific targeting across multiple CDN-harboring genes.\"}]","Characterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patients | PDF",1790045796,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5ab1ae8b0dd91246d533a718d2a6e8d.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f802d06f164b36a123cfef9f72bb67b7.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d31169dc03259317613dada56b7cf75.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f762aa88b6fbf87ffe4708b0c99f1272.webp",980,1268]